Third Party Certification for Drugs Associated With an Import Alert Exception

Posted 24 November 2017 By Allyn R. Becker, PhD, Mark Lookabaugh

placeholder+image The US Food and Drug Administration (FDA) has begun a widely recognized campaign of intensified surveillance of foreign manufacturers of Active Pharmaceutical Ingredients (APIs) and finished drug products. Failure to comply with the regulatory requirements for good manufacturing practice can subject a foreign firm to an import alert, thereby cutting off access to commercial distribution in the US. This article provides an overview of the consequences of an import alert and the steps that may be required to have an alert lifted by FDA.

Share this article:

Categories: Active pharmaceutical ingredients, Drugs, Distribution, Manufacturing, Features, US, FDA

Tags: Third Party Certification, Import Alert

Regulatory Exchange: Latest Updates From the Community